1. Lozada C, Steigelfest E. Osteoarthritis. Medicine Rheumatology 2010; 15:12-23 2. Raynauld JP, Martel-Pelletier J, Haraoui B, Pelletier JP. Chapter 25. Osteoarthritis-arthrosis short term studies: pain and function improvement in Osteoarthritis 2002, pages 294 – 306. 3. Garstang SV, Stitik TP. Osteoarthritis: epidemiology, risk factors, and pathophysiology. Am J Phys Med Rehabil 2006; 85:S2–S11. 4. Tsumura H, Tamura I, Tanaka H, et al. Prescription of non-steroidal anti-inflammatory drugs and co-prescribed drugs for mucosal protection: analysis of the present status based on questionnaires obtained from orthopaedists in Japan. Intern Med. 2007; 46:927- 931. 5. Zhang W, Moskowitz RW, Nuki G, et al. OARSI Recommendations for the management of hip and knee osteoarthritis. part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007; 15: 981–1000 6. Bierma-Zeinstra SM, Koes BW. Risk factors and prognostic factors of hip and knee osteoarthritis. Nat Clin Pract Rheumatol. 2007; 3:78-85. 7. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol. 2007; 213: 626–634. 8. Martel-Pelletier J. Pathophysiology of osteoarthritis. Osteoarthritis Cartilage 2004; 12 (Suppl A):S31–S33. 9. Chevalier X, Mugnier B, Bouvenot G, Chevalier X, Mugnier B, Bouvenot G. Targeted anti-cytokine therapies for osteoarthritis]. [Review] [French] Bull Acad Nationale Medecine. 2006; 190:1411–1420 10. Roddy E, Doherty M. Changing life-styles and osteoarthritis: what is the evidence?. Best Pract Res Clin Reumatol. 2006; 20:81-97. 11. Lee YC, Shmerling RH. The benefit of nonpharmacologic therapy to treat symptomatic osteoarthritis. Curr Rheumatol Rep. 2008; 10:5-10. 12. Zhang W, Moskowitz RW, Nuki G, et al. OARSI Recommendations for the management of hip and knee osteoarthritis. part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage. 2007; 15:981–1000. 13. Zhang W, Moskowitz R, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008; 16: 137-162. 14. Bannwarth B. Acetaminophen or NSAIDs for the treatment of osteoarthritis. Best Pract Res Clin Rheumatol 2006, 20:117-129 15. Kobayakawa M, Uemura N. Prevention and treatment of non-steroidal anti-inflammatory drugs induced ulcers in osteoarthritis. Nippon Rinsho 2007, 65: 1857-1861. 16. Scanzello CR, Moskowitz NK, et al. The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Curr Rheumatol Rep. 2008; 10:49-56. 17. Mikhail SS, Zwar NA, Vagholkar S, Dennis SM, Day RO. Non-steroidal anti-inflammatory drugs in general practice: a decision-making dilemma. Med J Aust. 2007; 187: 160-163. 18. Yajima H, Yamao J, Fukui H, Takakura Y. Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopaedic outpatients: a study using logistic regression analysis. J Orthop Sci 2007, 12: 341-346 19. Mitchell J., Warner T. Discontinuation of Vioxx. The Lancet 2004, 365,9453: 27-28 20. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475-81. 21. Kimmel SE, Berlin JA, Reilly M, et al.: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005, 142:157-64. 22. Lamarque D. Pathogenesis of gastroduodenal lesions induced by non-steroidal anti-inflammatory drugs. Gastroenterol Clin Biol. 2004, 28: C18-26 23. Whittle BJ. Gastrointestinal effects of non-steroidal anti-inflammatory drugs. Fundam Clin Pharmacol. 2003;17:301–313 24. Kountouras J, Chatzopoulos D., Zavos C. Reactive oxygen metabolites and upper gastrointestinal diseases. Hepatogastroenterology 2001, 48: 743 – 751 25. Demir S, Yilmaz M, Koseoglu M, Akalin N, Aslan D, Aydin A. Role of free radicals in peptic ulcer and gastritis. Turkish J. Gastroenterology, 2003. 14 : 39-43 26. Pohle T, Brzozowski T, Becker JC, Van Der Voort IR, et al. Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin C. Aliment Pharmacol Ther. 2001; 15:677–687 27. Lin J., Zhang W. et al. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 2004;329:324 28. Cepeda MS, Camargo F. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2006; CD005522. 29. Towheed TE, Maxwell L, Judd M, Cotton M, Huchberg MC, Wells GA. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006; January 25 (1):CD004257. 30. Strauss EJ, Hart JA, Miller MD, Altman RD, Rosen JE. Hyaluronic acid viscosupplementation and osteoarthritis: current uses and future directions. Am J Sports Med. 2009; 37:1636-1644. 31. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256. 32. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulphate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113-2123. 33. McAlindon T: Why are clinical trials of glucosamine no longer uniformly positive? Rheum Dis Clin North Am 2003, 29:789-801. 34. McAlindon TE, Formica M, LaValley M, et al. Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial. Am J Med 2004, 117:643-649. 35. Huskisson EC. Glucosamine and chondroitin for osteoarthritis. J Int Med Res. 2008; 36:1161-1179. 36. Piscoya J, Rodríguez Z, Bustamante SA, et al. Efficacy and safety of freeze-dried cat's claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflamm Res 2001, 50:442-448. 37. Ahmed S, Rahman A, Hasnain A, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1β-induced activity and expression of cyclo-oxygenase-2 and nitric oxide synthase-2 activity in human chondrocytes. Free Radical Biology Med 2002, 33:1097-1105 38. Walter-Bone K: 'Natural remedies' in the treatment of osteoarthritis. Drugs & Aging 2003, 20:517-526 39. Miller M, Mehta K, Kunte S, et al. Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: a randomized controlled trial. J Inflamm. 2005; 2:11-17. 40. Frestedt JL, Walsh M, Koskowski M, Zenk J. A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized, controlled pilot trial. Nutrition J. 2008; 7:9-13. 41. Cisar P. Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis. Phytoher Res. 2008; 22: 518-523. 42. Frech TM, Clegg DO. The utility of nutraceuticals in the treated of osteoarthritis. Rheumatol Rep. 2007; 9:25-30. 43. Mas R. Abexol: Beeswax alcohols. Drugs of the Future. 2001; 26:731-744. 44. Menéndez R., Amor AM, González RM, et al. Inhibition of rat microsomal lipid peroxidation by the oral administration of Abexol. Brazil J Med Biol Res. 2000; 33: 85-90. 45. Molina V, Valdés S, Carbajal D, et al. Antioxidant effects of Abexol on gastric mucosa of rats with injury induced experimentally. J Med Food. 2001; 4: 79-84. 46. Pérez Y, González R, Amor AM, et al. Abexol on antioxidant enzymes in liver and brain of rats. Rev CENIC Cien Biol. 2002; 33:3-5. 47. Mendoza S, Noa M, Perez Y, Más R. Preventive effect of Abexol, a mixture of long-chain alcohols from beeswax, on the liver damage induced with CCl4 in rats. J Med Food. 2007;10: 379-383. 48. Menéndez R, Más R, Amor AM, et al. Antioxidant effects of Abexol on the in vitro susceptibility in healthy volunteers. Arch Med Res. 2001; 32: 436-441. 49. Menéndez R, Más R, Illnait J, et al. Effects of Abexol on lipid peroxidation in older subjects. J Med Food. 2001; 4: 71-77. 50. López E, Illnait J, Molina V, et al. Effects of Abexol (beeswax alcohols) on lipid peroxidation in middle-aged and older subjects. LAJP. 2008; 27: 695-703. 51. Rodriguez I, Illnait J, Molina V, et al. Comparison of the antioxidant effects of Abexol (beeswax alcohols) and grape seed extract (GSE) on plasma oxidative variables in healthy subjects LAJP. 2009,4:21-26. 52. Pérez Y, Oyarzábal A, Ravelo Y, Mas R, Jiménez S, Molina V. Inhibition of COX and 5-LOX enzymes by D-002 (beeswax alcohols). Current Top Nutraceutical Research 2012 (in press) 53. James P. Hardwick, Douglas Osei - Hyiaman, Homer Wiland,1 Mohamed A. Abdelmegeed, and Byoung-Joon Song. PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid ω-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease. PPAR Research. Volume 2009, Article ID 952734, 20 pages. 54. Peter Lobby. Current Concepts of the Pathogenesis of the Acute Coronary Syndromes Circulation. 2001;104:365-372 55. Loeser RF. Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the cartilage matrix. Osteoarthritis Cartilage 2009;17:971–9., 56. Carbajal D, Molina V, Valdés S, et al. Anti-inflammatory activity of Abexol: an active product isolated from beeswax. Prostag Leuk Essent Fatty Acids. 1998;59:235-238 57. Ravelo Y, Molina V, Carbajal D, et al. Effects of single oral and topical administration of D-002 (beeswax alcohols) on xylene induced ear edema in mice. LAJP 2010, 29: 58. Ravelo Y, Molina V, Carbajal D, et al. Evaluation of anti-inflammatory and antinociceptive effects of Abexol (beeswax alcohols). J Nat Med. 2010; 65:330-335. 59. Carbajal D, Molina V, Valdés S, et al. Anti-ulcer activity of higher primary alcohols of beeswax. J Pharm Phamacol 1995, 47: 731-733 60. Carbajal D, Molina V, Valdés S, et al. Possible cytoprotective mechanism in rats of Abexol an anti-ulcerogenic product isolated from beeswax. J Pharm Pharmacol. 1996;48:858-860. 61. Carbajal D, Molina V, Noa M, et al. Effects of Abexol on gastric mucus composition in ethanol induced ulcer. Pharmacol Res. 2000; 42:329-332. 62. Illnait J, Terry H, Más R, et al. Effects of Abexol, a product isolated from beeswax, on gastric symptoms of patients with osteoarthritis treated with piroxicam: a pilot study. J Med Food. 2005; 8:63-68. 63. Rodríguez I, Illnait J, Terry H, et al. Effects of Abexol (beeswax alcohols) on the gastrointestinal symptoms of middle-aged and elderly subjects. Rev CENIC Cien Biol. 2009; 40:3-8. 64. Hano O, Illnait J, Más R, et al. Effects of Abexol, a product isolated from beeswax, on duodenal ulcer: A double-blind, placebo-controlled study. Curr Ther Res. 2001; 62:394-407. 65. Fernández JC, Rodríguez I, Illnait J, Fernández L, Mas R, Pérez Y, Gámez R, Mesa M, Jiménez S, Mendoza S, Ruiz D. Effects of Abexol (beeswax alcohols) in patients with gastric symptoms. Rev CENIC Cien Biol 2012;43(1):9-16. 66. Fernández L, Terry H, Quiñones AM, et al. Effects of Abexol in middle-aged and older subjects: an open follow-up. Rev CENIC Cien Biol. 2008; 39:3-8. 67. Rodeiro I, Alemán C, Noa M, et al. Preclinical oral toxicology in rats of Abexol, a natural drug with antiulcer effects. Drug Chem Tox. 1998; 21:151-163. 68. Rodeiro I, Gámez R, Acosta PC, et al. Estudio genotoxico del Abexol, un producto con actividad antiulcerosa Rev Esp Tox. 1998; 15:117-121. 69. Rodríguez MD, Gámez R, Sánchez M, García H. Developmental toxicity of Abexol, a mixture of aliphatic primary alcohols in rats and rabbits. J Appl Toxicol. 1998; 18:313-316. 70. Rodeiro I, Alemán C, Noa M, et al. Oral toxicological studies of Abexol in mice. Rev CENIC Cien Biol. 1999;30:73-75. 71. Alemán C, Rodeiro I, Noa M, et al. A one-year study of Abexol. a mixture of aliphatic primary alcohols in Beagle dogs. J Appl Toxicol. 2000; 20:427-432. 72. Horton, Derek; Wander, J.D. (1980). The Carbohydrates Vol IB. New York: Academic Press. pp. 727-728 73. Mas R. D-003: A new substance with promising lipid modifying and pleiotropic effects for atherosclerosis management. Drugs of the Future 2004, 29: 773 – 786 74. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, Hochberg MC, Wells G. Terapia con glucosamina para el tratamiento de la osteoartritis. La Biblioteca Cochrane Plus 2011 Número 1 ISSN 1745-9990 75. Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung. 2001 Sep; 51(9):699-725. 76. Williams & Wilkins. Basic Medical Biochemistry: A Clinical Approach. 1996: 452-453. 77. Murray, Michael, T. Glucosamine sulfate: nature’s arthritis cure. Excerpt from The Chiropractic Journal – March 1998 78. Loeser RF. Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the cartilage matrix. Osteoarthritis Cartilage 2009;17:971–9 79. Vidal, Y., and Plana, R.R., et al. Articular cartilage pharmacology. Altern Med Rev 1999 Jun; 4(3): 193-5. 80. Deal, C.L., Moskowitz, R.W. Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am, 1000 May; 25 (2): 379-95 81. Reginster, J.Y., Deroisy, R., Rovati, L.C., Lee, R.L., Lejeune, E., Bruyere, O., Giacovelli, G., Henrotin, Y., Dacre, J.E., and Gossett, C., 'Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled trial,' Lancet. 2001;357:251-256) 82. Barclay, T.S., Tsourounis, C., McCart, G.M. Glucosamine. Ann Pharmacother 1998 May; 32 (5): 574-9 83. Gottlieb, Marc S. Conservative Management of Spinal Osteoarthritis with Glucosamine Sulfate and Chiropractic Treatment. Journal of Manipulative and Physiological Therapeutics, Volume 20, (6) July/August, 1997 84. Delafuente, J.C. Glucosamine in the treatment of osteoarthritis,' Rheumatic Disease Clinics of North America. 2000;26(1):1-11 85. Batlle-Gualda E, Esteve-Vives J, Piera MC, Hargreaves R, Cutts J. Adaptación transcultural al cuestionario WOMAC especifico para artrosis de rodilla y cadera. Rev Esp Reumatol. 1999; 26:38-45. 86. Angst T, Aeschlimann A, Stuki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implication for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis and Rheumatism. 2001; 45:384-391. 87. Altman R, Asch E, Bloch D, et al. The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum 1986, 9:1039-1049 88. Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991, 34:505 – 514 89. Requerimientos para la notificacion y el reporte de eventos adversos graves e inesperados en los ensayos clínicos. Regulacion No. 45-2007. CECMED, 2007. 90. O’Brien P.C, Shampo M.C. Statistical considerations for performing multiple tests in a single experiment 5. Comparing two therapies with respect to several endpoints. Mayo Clin Proc. 1988, 63: 1140-1143.